Sanjivani Paranteral Limited Share Price

Equities

SANJIVIN

INE860D01013

Pharmaceuticals

Market Closed - Bombay S.E. 05:05:39 21/05/2024 BST 5-day change 1st Jan Change
187.5 INR +0.73% Intraday chart for Sanjivani Paranteral Limited +1.30% +4.11%

Financials

Sales 2022 306M 3.68M 289M Sales 2023 355M 4.26M 335M Capitalization 414M 4.97M 391M
Net income 2022 48M 576K 45.36M Net income 2023 45M 540K 42.53M EV / Sales 2022 2.32 x
Net Debt 2022 56.54M 679K 53.44M Net Debt 2023 21.91M 263K 20.71M EV / Sales 2023 1.23 x
P/E ratio 2022
13.5 x
P/E ratio 2023
9.19 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 50.58%
More Fundamentals * Assessed data
Dynamic Chart
Sanjivani Parenterals CFO Steps Down MT
Sanjivani Paranteral Limited Announces Board Changes CI
Sanjivani Paranteral Limited Announces CFO Change CI
Sanjivani Paranteral Forms New Unit MT
Sanjivani Paranteral Limited Appoints Pooja Vijay Gohil as Company Secretary and Compliance Officer CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Sanjivani Paranteral Limited announced that it has received INR 248.0466 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt. Ltd., Venus Orchards Pvt. Ltd., Ashika Global Securities Private Limited CI
Sanjivani Paranteral Limited announced that it expects to receive INR 248.0346 million in funding from Nabs Vriddhii LLP, Plasma Commercials Pvt.Ltd., Venus Orchards Pvt. Ltd, Ashika Global Securities Private Limited and other investors CI
Sanjivani Paranteral Limited Announces Resignation of Ritu Puglia from the Position of the Company Secretary CI
Sanjivani Paranteral Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Sanjivani Paranteral Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Sanjivani Paranteral Ties Up with Czech Republic-based Alevia Healthcare to Expand Business in EU MT
Sanjivani Paranteral Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Sanjivani Paranteral Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
More news
1 day+0.73%
1 week+1.30%
Current month-0.66%
1 month-3.25%
3 months+9.08%
6 months+26.69%
Current year+4.11%
More quotes
1 week
180.00
Extreme 180
192.70
1 month
171.80
Extreme 171.8
204.95
Current year
122.15
Extreme 122.15
204.95
1 year
54.50
Extreme 54.5
204.95
3 years
10.64
Extreme 10.64
204.95
5 years
5.35
Extreme 5.35
204.95
10 years
3.17
Extreme 3.17
204.95
More quotes
Managers TitleAgeSince
Chief Executive Officer 53 31/12/96
Members of the board TitleAgeSince
Chief Executive Officer 53 31/12/96
Director/Board Member 55 30/03/15
Director/Board Member 50 23/03/22
More insiders
Date Price Change Volume
21/05/24 187.5 +0.73% 1 033
18/05/24 186.2 +1.09% 2,232
17/05/24 184.2 -1.71% 5,822
16/05/24 187.4 -1.42% 9,118
15/05/24 190 +2.67% 10,678

Delayed Quote Bombay S.E., May 21, 2024 at 05:05 am

More quotes
Sanjivani Paranteral Limited is engaged in the business of manufacturing pharmaceutical products. Its product category includes antibiotic, anti-emetic, non-steroidal anti-inflammatory drugs (NSAID) and analgesic, antimalarial, calcium and vitamin, sedative, steroid, cardiovascular, anti-fibrinolytic, anti-coagulant, vasoconstrictor, inotropic agent, anti-spasmodic, multivitamin, nutrition, iron, NSAID and analgesic, analgesic anti spasmodic, analgesic, and NSAID. Its antibiotic includes Netilmicin Sulphate, Amikacin Sulphate, and Gentamycin Sulphate. Its anti-emetic includes Ranitidine Hydrochloride, Metoclopramide, Ondansetron, and Promethazine. Its NSAID and analgesic includes Acetaminophen Injection and Diclofenac Sodium Injection. Its calcium and vitamin include Methylcobalamin 500 mcg/ml and Nicotinic Acid 10 mg/ml. Its sedative includes Midazolam Hydrochloride, Diazepam, and Dobutamine Hydrochloride. Its Iron includes iron Sucrose. Its analgesic includes Metamizole.
More about the company
  1. Stock Market
  2. Equities
  3. SANJIVIN Stock